Renaissance Technologies’s aTyr Pharma ATYR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $98.6K | Buy |
4,131
+3,118
| +308% | +$81.5K | ﹤0.01% | 2980 |
|
|
2026
Q1 | $31.6K | Buy |
+1,013
| New | +$34.2K | ﹤0.01% | 3139 |
|
|
2025
Q3 | – | Sell |
-12,959
| Closed | -$2.63M | – | 4020 |
|
|
2025
Q2 | $2.63M | Buy |
12,959
+960
| +8% | +$151K | ﹤0.01% | 1940 |
|
|
2025
Q1 | $1.45M | Sell |
11,999
-2,362
| -16% | -$344K | ﹤0.01% | 2189 |
|
|
2024
Q4 | $2.08M | Sell |
14,361
-14,368
| -50% | -$1.74M | ﹤0.01% | 2026 |
|
|
2024
Q3 | $2.02M | Sell |
28,729
-3,616
| -11% | -$263K | ﹤0.01% | 2013 |
|
|
2024
Q2 | $2.02M | Buy |
32,345
+524
| +2% | +$36.5K | ﹤0.01% | 1881 |
|
|
2024
Q1 | $2.48M | Buy |
31,821
+9,872
| +45% | +$689K | ﹤0.01% | 1887 |
|
|
2023
Q4 | $1.24M | Buy |
21,949
+9,299
| +74% | +$477K | ﹤0.01% | 2262 |
|
|
2023
Q3 | $799K | Sell |
12,650
-509
| -4% | -$37.7K | ﹤0.01% | 2453 |
|
|
2023
Q2 | $1.14M | Buy |
13,159
+9,218
| +234% | +$805K | ﹤0.01% | 2391 |
|
|
2023
Q1 | $331K | Sell |
3,941
-211
| -5% | -$18.5K | ﹤0.01% | 3068 |
|
|
2022
Q4 | $364K | Sell |
4,152
-536
| -11% | -$50.5K | ﹤0.01% | 3131 |
|
|
2022
Q3 | $563K | Buy |
4,688
+917
| +24% | +$123K | ﹤0.01% | 2861 |
|
|
2022
Q2 | $427K | Buy |
3,771
+1,000
| +36% | +$145K | ﹤0.01% | 3247 |
|
|
2022
Q1 | $593K | Sell |
2,771
-408
| -13% | -$92.5K | ﹤0.01% | 3080 |
|
|
2021
Q4 | $950K | Sell |
3,179
-1,312
| -29% | -$438K | ﹤0.01% | 2683 |
|
|
2021
Q3 | $1.63M | Buy |
4,491
+85
| +2% | +$20.3K | ﹤0.01% | 2251 |
|
|
2021
Q2 | $860K | Sell |
4,406
-1,643
| -27% | -$280K | ﹤0.01% | 2738 |
|
|
2021
Q1 | $1.08M | Sell |
6,049
-1,929
| -24% | -$363K | ﹤0.01% | 2584 |
|
|
2020
Q4 | $1.24M | Sell |
7,978
-2,233
| -22% | -$327K | ﹤0.01% | 2395 |
|
|
2020
Q3 | $1.32M | Buy |
10,211
+1,065
| +12% | +$175K | ﹤0.01% | 2359 |
|
|
2020
Q2 | $1.62M | Buy |
9,146
+3,921
| +75% | +$569K | ﹤0.01% | 2291 |
|
|
2020
Q1 | $585K | Buy |
5,225
+227
| +5% | +$39.2K | ﹤0.01% | 2682 |
|
|
2019
Q4 | $834K | Buy |
4,998
+157
| +3% | +$24.3K | ﹤0.01% | 2712 |
|
|
2019
Q3 | $678K | Buy |
4,841
+1,545
| +47% | +$228K | ﹤0.01% | 2748 |
|
|
2019
Q2 | $676K | Buy |
3,296
+545
| +20% | +$148K | ﹤0.01% | 2872 |
|
|
2019
Q1 | $847K | Buy |
2,751
+308
| +13% | +$87.7K | ﹤0.01% | 2746 |
|
|
2018
Q4 | $678K | Buy |
2,443
+466
| +24% | +$156K | ﹤0.01% | 2745 |
|
|
2018
Q3 | $899K | Buy |
1,977
+1,024
| +107% | +$448K | ﹤0.01% | 2646 |
|
|
2018
Q2 | $486K | Buy |
953
+260
| +38% | +$247K | ﹤0.01% | 2842 |
|
|
2018
Q1 | $1.03M | Buy |
693
+194
| +39% | +$364K | ﹤0.01% | 2648 |
|
|
2017
Q4 | $978K | Buy |
499
+294
| +143% | +$723K | ﹤0.01% | 2665 |
|
|
2017
Q3 | $580K | Buy |
205
+97
| +90% | +$180K | ﹤0.01% | 2749 |
|
|
2017
Q2 | $205K | Buy |
108
+39
| +57% | +$73K | ﹤0.01% | 2994 |
|
|
2017
Q1 | $136K | Buy |
69
+1
| +1% | +$1.83K | ﹤0.01% | 3043 |
|
|
2016
Q4 | $82K | Sell |
68
-56
| -45% | -$91.9K | ﹤0.01% | 3125 |
|
|
2016
Q3 | $220K | Buy |
+124
| New | +$214K | ﹤0.01% | 3048 |
|
Other funds holding ATYR
KCM
Renaissance Technologies's ATYR Position: Q2 2026 in Review
Renaissance Technologies increased its aTyr Pharma (ATYR) stake by 308% in Q2 2026, buying an estimated $81.5K and bringing the position to 4,131 shares worth $98.6K. The position accounts for ﹤0.01% of the portfolio, ranked #2980.
Renaissance Technologies first reported a position in ATYR in Q3 2016 and has held it in 38 quarters since. The position peaked at $2.63M in Q2 2025. 87 funds tracked by Wall St. Rank hold ATYR as of Q2 2026.
- Renaissance Technologies held 4,131 shares of aTyr Pharma worth $98.6K as of Q2 2026.
- Renaissance Technologies bought 3,118 aTyr Pharma shares in Q2 2026, an estimated $81.5K.
- aTyr Pharma made up ﹤0.01% of Renaissance Technologies's portfolio in Q2 2026, its #2980 holding.
- Renaissance Technologies first reported a position in aTyr Pharma in Q3 2016 and has held it in 38 quarters since.
- Renaissance Technologies's aTyr Pharma position peaked at $2.63M in Q2 2025.
- 87 funds tracked by Wall St. Rank held aTyr Pharma as of Q2 2026.
Based on Renaissance Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.